Surgical Bleeding Pipeline Analysis Report 2026

Report Coverage

The Surgical Bleeding Pipeline Analysis Report by Expert Market Research gives comprehensive insights into Surgical Bleeding therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Surgical Bleeding. The Surgical Bleeding report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The Surgical Bleeding pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with Surgical Bleeding treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to Surgical Bleeding.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Surgical Bleeding Pipeline Outlook

The surgical bleeding pipeline is evolving to improve intraoperative bleeding control and surgical outcomes across multiple specialties. Rising surgical volumes and the growing need for effective hemostasis continue to support pipeline expansion. In December 2025, the U.S. FDA granted Premarket Approval for ETHIZIA™, an absorbable collagen-based hemostatic patch from Ethicon for use in open liver surgery. Surgical bleeding pipeline analysis by Expert Market Research highlights sustained development of advanced biological hemostats, recombinant coagulation factors, and next-generation bleeding control solutions.

Surgical Bleeding Epidemiology

Surgical bleeding is a major global healthcare challenge that significantly increases postoperative morbidity and mortality. More than 300 million surgical procedures are performed worldwide each year, with approximately 4.2 million patients dying within 30 days after surgery. Clinically significant bleeding occurs in about 1.5% to 17% of surgical patients, depending on the procedure and definition used. Evidence indicates that patients experiencing major surgical bleeding have a substantially higher risk of death, and major bleeding may contribute to 20-32% of postoperative deaths globally.

Surgical Bleeding – Pipeline Therapeutic Assessment

Surgical Bleeding Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, surgical bleeding pipeline is led by phase 3 (38.30%) candidates, followed by phase 4 (29.79%), reflecting a mature development landscape. Phase 2 accounts for 19.15%, while early phase 1 (8.51%) and Phase 1 (4.26%) represent emerging innovations advancing through early clinical evaluation.

Surgical Bleeding Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the Surgical Bleeding pipeline analysis include biologicals, recombinant proteins/coagulation factors, and peptide-based therapies. The Surgical Bleeding report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for Surgical Bleeding. In November 2024, the U.S. FDA approved an expanded indication for VISTASEAL™ (Grifols) for pediatric patients, enabling its use as an adjunct to control surgical bleeding when conventional hemostatic techniques are inadequate.

Surgical Bleeding Clinical Trials – Key Players

The EMR report for the Surgical Bleeding pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed Surgical Bleeding therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in Surgical Bleeding clinical trials:

• Northwell Health
• Corza Medical GmbH
• Hamilton Health Sciences Corporation
• CSL Behring
• Ottawa Heart Institute Research Corporation
• Grifols Biologicals, LLC
• Johns Hopkins Aramco Healthcare
• Dilon Technologies
• Hemostasis, LLC
• Medcura, Inc.
• Sealantium Medical Ltd.

Surgical Bleeding – Emerging Drugs Profile

Key Questions Answered in the Surgical Bleeding Pipeline Insight Report

• Which companies/institutions are leading the Surgical Bleeding drug development?
• Which company is leading the Surgical Bleeding pipeline development activities?
• What is the current Surgical Bleeding commercial assessment?
• What are the opportunities and challenges present in the Surgical Bleeding pipeline landscape?
• What is the efficacy and safety profile of Surgical Bleeding pipeline drugs?
• Which company is conducting major trials for Surgical Bleeding drugs?
• Which companies/institutions are involved in Surgical Bleeding collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in Surgical Bleeding?

Reasons To Buy This Report

The Surgical Bleeding Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for Surgical Bleeding. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into Surgical Bleeding collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Clinical Trials Market

Bleeding Disorders Therapeutics Market

Bleeding Disorders Treatment Market